Agio Capital & Business Solutions is an international advisory boutique providing financial & business solutions and services. Although we work globally, we focus mainly on Europe and Asia (in particular China). We work closely together with our sister company Agio Law which offers legal services & advisory. In total Agio Capital and Agio Law have a staff of 30 people. Via our offices in Belgium, Hong Kong and Shanghai, our experienced teams we work closely with leading businesses, corporates, strategic and financial investors. Our customers are mainly those high-tech businesses with a compelling opportunity for growth, internationally or domestically. One of our main focus points are companies in the life science & healthcare sector. Our core strengths lie in our international network, deep sector expertise, transparency, no-nonsense approach & culture.
MEET AGIO CAPITAL & BUSINESS SOLUTIONS @ #KFG2019
Agio Capital & Business Solutions will present a workshop in the PM workshop session.
"Doing biotech business in China: Risk or Big Opportunity?"
In the past 30 years, China has become a global powerhouse and a major market for foreign companies.
With more than 400 million Chinese citizens demanding and capable of paying state-of-the-art healthcare, China is now focusing on the development of its life sciences and healthcare sector. A recent study by Mckinsey has demonstrated that China has invested more capital in life sciences in 2018 than the USA. In addition, recent reforms of the China IP system and clinical trial system have been instigated with the goal to attract state-of-the-art healthcare technology into the Chinese healthcare system. All these measures are supported by the latest 5-year plan of the Chinese government. In fact this focus on technology is actually the primary reason for the current trade war between the US and China.
Despite the resources China is committing to this area, Chinese biotech and pharma companies are still lagging far behind in the development of innovative state-of-the-art therapeutics and diagnostics. This in combination with the available capital results in a high interest from China in western technologies. The recent US protectionism has also increasingly directed the interest of China towards European biotech.
This workshop organized by Agio Capital & Business Solutions, an international investment advisory with offices in Belgium, Hong Kong and Shanghai, wants to update the current view on the life science sector in China, its huge opportunities and pitfalls. Concerns on IP and clinical studies will be answered and strategies will be presented on how to raise capital from Chinese investors, and how to set up partnerships and deals with Chinese biotech and pharma companies.